HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

William A Wegener Selected Research

veltuzumab

11/2016Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.
1/2016Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia.
6/2015The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
12/2014Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.
11/2014Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
9/2013Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.
4/2011Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.
5/2010Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.
7/2009Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


William A Wegener Research Topics

Disease

13Neoplasms (Cancer)
01/2019 - 05/2005
12Non-Hodgkin Lymphoma (Lymphosarcoma)
06/2015 - 08/2003
5Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2017 - 08/2008
5Lymphoma (Lymphomas)
11/2014 - 07/2005
4Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2021 - 01/2006
4Neutropenia
10/2017 - 06/2011
3Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2017 - 08/2004
3Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
11/2016 - 05/2010
3Pancreatic Neoplasms (Pancreatic Cancer)
09/2015 - 06/2011
2Triple Negative Breast Neoplasms
01/2019 - 07/2017
2Colorectal Neoplasms (Colorectal Cancer)
10/2017 - 09/2005
2Thrombocytopenia (Thrombopenia)
01/2017 - 06/2011
2B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2016 - 11/2008
2Adenocarcinoma
09/2015 - 06/2011
2Hematologic Neoplasms (Hematological Malignancy)
07/2015 - 12/2013
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
07/2009 - 08/2005
2B-Cell Lymphoma (Lymphoma, B Cell)
08/2005 - 07/2005
1Disease Progression
01/2019
1Body Weight (Weight, Body)
01/2019
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2017
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/2017
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2017
1Hemorrhage
11/2016
1Residual Neoplasm
07/2015
1Pathologic Complete Response
12/2014
1Pemphigus (Pemphigus Vulgaris)
12/2014
1Philadelphia Chromosome
12/2013
1Multiple Myeloma
11/2013
1Pancreatic Ductal Carcinoma
11/2012
1Autoimmune Diseases (Autoimmune Disease)
05/2010
1Fatigue
01/2006
1Neoplasm Metastasis (Metastasis)
09/2005
1Appendicitis
09/2004

Drug/Important Bio-Agent (IBA)

14epratuzumabIBA
01/2018 - 08/2003
9veltuzumabIBA
11/2016 - 07/2009
8Monoclonal AntibodiesIBA
11/2013 - 08/2003
6sacituzumab govitecanIBA
01/2019 - 09/2015
6Immunoconjugates (Immunoconjugate)IBA
10/2017 - 09/2015
61,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
01/2017 - 07/2005
6Rituximab (Mabthera)FDA Link
12/2014 - 08/2005
5Irinotecan (Camptosar)FDA LinkGeneric
01/2019 - 09/2015
3milatuzumabIBA
01/2021 - 11/2013
3Immunoglobulin G (IgG)IBA
01/2018 - 01/2006
3Pharmaceutical PreparationsIBA
08/2017 - 05/2005
3AntibodiesIBA
06/2015 - 05/2005
2Carcinoembryonic AntigenIBA
10/2017 - 09/2005
2YttriumIBA
09/2015 - 12/2013
2GemcitabineFDA Link
09/2015 - 11/2012
2MucinsIBA
09/2015 - 06/2011
2ORALIT (ORS)IBA
07/2009 - 08/2004
1macrophage migration inhibitory factor receptorIBA
01/2021
1Macrophage Migration-Inhibitory FactorsIBA
01/2021
1labetuzumab govitecanIBA
10/2017
1Cell Adhesion MoleculesIBA
10/2017
1Glucuronosyltransferase (UDP Glucuronosyltransferase)IBA
10/2017
1Uridine Diphosphate (UDP)IBA
10/2017
17-ethyl-10-hydroxycamptothecin beta-glucuronideIBA
10/2017
1CamptothecinIBA
10/2017
1Type I DNA Topoisomerases (Topoisomerase I)IBA
10/2017
1Biomarkers (Surrogate Marker)IBA
08/2017
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
09/2015
1Vincristine (Oncovin)FDA LinkGeneric
04/2015
1Dexamethasone (Maxidex)FDA LinkGeneric
04/2015
1Investigational DrugsIBA
12/2014
1SteroidsIBA
09/2013
1Immunoglobulins (Immunoglobulin)IBA
09/2013
1Inosine Triphosphate (ITP)IBA
09/2013
1clivatuzumabIBA
11/2012
1Glycoproteins (Glycoprotein)IBA
06/2011
1Complement System Proteins (Complement)IBA
05/2010
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
07/2009
1Radioisotopes (Radionuclides)IBA
07/2005
1Proteins (Proteins, Gene)FDA Link
07/2005
1Immunotoxins (Immunotoxin)IBA
05/2005
1Humanized Monoclonal AntibodiesIBA
05/2005
1SulesomabIBA
09/2004
1Immunoglobulin Fab FragmentsIBA
09/2004
1Technetium (Technetium 99m)IBA
09/2004

Therapy/Procedure

14Therapeutics
01/2019 - 05/2005
11Radioimmunotherapy
01/2017 - 07/2005
4Drug Therapy (Chemotherapy)
01/2019 - 08/2008
4Subcutaneous Injections
11/2016 - 05/2010
3Immunotherapy
11/2013 - 01/2006
1Induction Chemotherapy
01/2017
1Transplantation
01/2017
1Injections
01/2016
1Stem Cell Transplantation
11/2014